TAPO in first-line osimertinib therapy and continuation of osimertinib.

Chihiro MimuraKazumi KaneshiroShodai FujimotoRyota DokuniNatsuhiko IwamotoKanoko MatsumuraYukihisa HatakeyamaYuko KonoMotoko Tachihara

Published in: Thoracic cancer (2022)

This study showed that grade 1 D-ILD might include TAPO and that patients with TAPO might have good PFS. We need to consider the possibility of osimertinib continuation when lung opacities appear.

Keyphrases

small cell lung cancer
advanced non small cell lung cancer
epidermal growth factor receptor
interstitial lung disease
tyrosine kinase
stem cells
systemic sclerosis
bone marrow